Priced for one buyer, wanted by many: management describes new sources of demand converging on the same thing it already
The model's full reasoning — Q1 2016 call → NOWe need answer YES or NO based on transcript. Need determine if management describes demand for same thing company already makes/does now coming from more than one direction, widening demand base, and management responding with steps, numbers lag. Transcript: Curis developing drugs. Programs: CUDC-907, CA170, Erivedge. Need see if any existing offering has widened demand from multiple sources. Erivedge is commercialized by partners Genentech/Roche for advanced basal cell carcinoma. Roche initiated two clinical studies with Erivedge outside BCC: one in myelofibrosis with ruxolitinib, one in idiopathic pulmonary fibrosis with pirfenidone. This is about Erivedge being studied in new indications. But is that demand? It's clinical studies, not actual buyers/orders. Also Erivedge is already commercialized for BCC, but new uses are investigational, not yet approved. Management notes Roche initiated enrollment in two clinical studies. That's not real demand from new sources transacting. Also company's own programs are clinical stage. No widening of existing product demand. So answer NO. Need ensure no other. CUDC-907 Phase 2 targeting MYC alterations, but that's development. CA170 entering clinic. No. Thus NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
LINC · Q1 2024 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES Management describes the core offering—curriculum and training capabilities already in place—as now being applied in a new direction: B2B corporate upskilling contracts (e.g., the CMC agreement) alongside campus-based student programs. They explicitly state they are pursuing additional employer contracts and expanding corporate partnerships, with the new 5-year, $6 million CMC deal representing real, recent revenue that contributed nothing to the reported quarter and is still ramping up through site setup and staffing. This meets all three criteria as a single coherent development.
OPAD · Q3 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES The transcript shows management describing demand for renovations (already part of their core iBuyer operations) now coming from multiple directions: their own inventory, third-party B2B clients (nearly 50 clients, 127% increase in closed projects), and soon homeowners via Rental Captain.
PFIE · Q1 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with the demand base widening recently, and manageme...